Brazikumab/ Brazikumab (n = 52) | Placebo/ Brazikumab (n = 52) | Total (N = 104) | |
---|---|---|---|
Age, mean ± SD, y | 35.3 ± 11.1 | 37.8 ± 10.6 | 36.5 ± 10.9 |
Female, n (%) | 32 (61.5) | 31 (59.6) | 63 (60.6) |
Weight, mean ± SD, kg | 70.1 ± 21.0 | 71.9 ± 15.3 | 71.0 ± 18.3 |
Race, n (%) | |||
White | 50 (96.2) | 49 (94.2) | 99 (95.2) |
Non-White | 2 (3.8) | 3 (5.8) | 5 (4.8) |
Not Hispanic or Latino, n (%) | 48 (92.3) | 47 (90.4) | 95 (91.3) |
Disease duration, mean ± SD, y | 13.0 ± 9.7 | 12.1 ± 8.7 | 12.6 ± 9.2 |
CDAI, mean ± SD, pointsa | 321.9 ± 62.2 | 308.3 ± 55.8 | 315.1 ± 59.2 |
Prior use of anti-TNFα agents, n (%) | |||
1 | 18 (34.6) | 16 (30.8) | 34 (32.7) |
2 | 32 (61.5) | 31 (59.6) | 63 (60.6) |
≥ 3 | 2 (3.8) | 5 (9.6) | 7 (6.7) |
Corticosteroid use at baseline, n (%) | 28 (53.8) | 26 (50.0) | 54 (51.9) |
Immunomodulator use at baseline, n (%) | 15 (28.8) | 13 (25.0) | 28 (26.9) |